Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Non-Current Deffered Revenue (2020)

Historic Non-Current Deffered Revenue for Serina Therapeutics (SER) over the last 1 years, with Q4 2020 value amounting to $64000.0.

  • Serina Therapeutics' Non-Current Deffered Revenue changed N/A to $64000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $64000.0, marking a year-over-year change of. This contributed to the annual value of $64000.0 for FY2020, which is N/A changed from last year.
  • Serina Therapeutics' Non-Current Deffered Revenue amounted to $64000.0 in Q4 2020.
  • Over the past 5 years, Serina Therapeutics' Non-Current Deffered Revenue peaked at $64000.0 during Q4 2020, and registered a low of $64000.0 during Q4 2020.